Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
SBP GROUP Innovative Drug Naldemedine Approved for Marketing by NMPA
Recommend 6 Positive 13 Negative 2 |
||||
|
||||
|
SBP GROUP (01177.HK) announced that Naldemedine (generic name: Naldemedine Tosylate Tablets; brand name: Symproic), a Class 1 innovative drug exclusively licensed by the Group’s subsidiary Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ), has been approved for marketing by China’s National Medical Products Administration (NMPA) for the treatment of opioidinduced constipation (OIC) in adults. Auto-translated by AI This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. More Details
AASTOCKS Financial News |
||||
Copied to Clipboard
 |
||||
